NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Gate Bioscience

Gate Bioscience

Private
Brisbane, CaliforniaHealthcare & Life Scienceshttps://www.gatebio.com/

Last Round

Series B

Nov 13, 2025

Est. Valuation

$161M

Total Funding Raised

$135M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Gate Bioscience is a biotechnology company that develops small molecule drugs known as Molecular Gates to selectively eliminate disease-causing extracellular proteins at their source within cells.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

molecular gateprotein degradationoral therapeuticssmall-molecule drugsundruggable proteinsprotein secretionbiotech platformdrug discoverypreclinical biotechtargeted protein degradationTPDpharma collaborationdrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gate Bioscience Comps

Public and private peers based on sector, stage, and business model.

Gate Bioscience comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Gate Bioscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 13, 2025
Series ANov 1, 2023

Key People

Founding team and executive leadership

Raman Talwar

Co-founder and CTO

Founding Team

Jordi Mata-Fink

Co-Founder and CEO

Founding Team

Gate Bioscience Investors

Notable investors and investment history

Gate Bioscience investors
InvestorRounds
Andreessen HorowitzSeed, Series B, Series A
GVSeries A, Series B
ForbionSeries B
ARCH Venture PartnersSeries A, Series B
ARCH Venture PartnersSeries A, Series B
Versant VenturesSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 13, 2025

    $65M round completed.

  • Nov 13, 2025

    Vanessa Carle joins the board in connection with recent financing.

Gate Bioscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gate Bioscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gate Bioscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersBrisbane, California
Employee Range41
Year Founded2021
Last FundingNov 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.